<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Memantine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Memantine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Memantine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11268" href="/d/html/11268.html" rel="external">see "Memantine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F192478"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Namenda;</li>
<li>Namenda Titration Pak;</li>
<li>Namenda XR;</li>
<li>Namenda XR Titration Pack [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867458"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACT Memantine;</li>
<li>APO-Memantine;</li>
<li>Ebixa;</li>
<li>MED-Memantine;</li>
<li>PMS-Memantine;</li>
<li>RAN-Memantine [DSC];</li>
<li>RIVA-Memantine;</li>
<li>SANDOZ Memantine FCT</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F192491"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        N-Methyl-D-Aspartate (NMDA) Receptor Antagonist</li></ul></div>
<div class="block doa drugH1Div" id="F192480"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d3474adc-f148-4e15-8847-8fe86e7444a6">Alzheimer disease, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease, moderate to severe (monotherapy or in combination with a cholinesterase inhibitor): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Initial: 5 mg once daily; increase daily dose by 5 mg every week as tolerated to a target maximum dose of 20 mg/day. <b>Note:</b> Dose may be administered once daily or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22397651','lexi-content-ref-17243195','lexi-content-ref-18288936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22397651','lexi-content-ref-17243195','lexi-content-ref-18288936'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 7 mg once daily; increase daily dose by 7 mg every week as tolerated to a target maximum dose of 28 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23733403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23733403'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f31d5dd-8c2e-4f4c-aeb7-2f04acca998c">Dementia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dementia (ie, Parkinson disease dementia, dementia with Lewy bodies, comorbid vascular dementia) (monotherapy or in combination with a cholinesterase inhibitor) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: Initial: 5 mg once daily; increase dose by 5 mg every week as tolerated to a target maximum dose of 20 mg/day. <b>Note:</b> Dose may be administered once daily or in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19520613','lexi-content-ref-20729148','lexi-content-ref-NICE.2018','lexi-content-ref-12409683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19520613','lexi-content-ref-20729148','lexi-content-ref-NICE.2018','lexi-content-ref-12409683'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="37573964-f9ad-4e34-bd9e-84992b4f6e10">Neurocognitive toxicity of whole brain irradiation, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurocognitive toxicity of whole brain irradiation, prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> Initial: 5 mg once daily with the initiation of radiation; increase dose by 5 mg weekly as tolerated to a target maximum dose of 20 mg/day. Doses &gt;5 mg/day may be given in 2 divided doses. Continue for up to 6 months after completion of whole brain radiation therapy (WBRT) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23956241','lexi-content-ref-32058845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23956241','lexi-content-ref-32058845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> Initial: 7 mg once daily with the initiation of radiation; increase dose by 7 mg weekly as tolerated to a target maximum dose of 28 mg once daily. Continue for up to 6 months after completion of WBRT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32058845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32058845'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Discontinuation of therapy</i>: </b>Discontinuation of therapy may result in worsening of cognitive function. Avoid abrupt discontinuation except in the case of severe adverse drug reaction to minimize withdrawal symptoms (eg, altered mental status, hallucinations, delusions, insomnia, increased anxiety and agitation). In general, memantine should be tapered using a 50% dose reduction or stepwise reduction via available dose formulations every 4 weeks to the lowest dose prior to discontinuation. Consider re-initiation if clear worsening of the condition occurs after withdrawal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30771226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30771226'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Conversion from immediate release to extended release: </i></b> Begin the ER product the day after the last dose of the IR product.</p>
<p style="text-indent:-2em;margin-left:4em;">If current IR dose is 10 mg/day: Convert to ER capsule 14 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">If current IR dose is 20 mg/day: Convert to ER capsule 28 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Missed doses</i>
<i>: </i></b>If several days of dosing are missed with either formulation, dosing may need to be resumed at lower doses and retitrated.</p></div>
<div class="block dora drugH1Div" id="F50991142"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute: Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, may increase in 5 mg increments no more frequently than weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). However, predicted steady state exposures are 60% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16413248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16413248'])">Ref</a></span>) to 100% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22863669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22863669'])">Ref</a></span>) greater compared to those with normal kidney function; a reduced maximum dose may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Initial: 5 mg once daily; after at least 1 week of therapy and if tolerated, may increase to a target dose of 5 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute: Initial: 7 mg once daily; after at least 1 week of therapy and if tolerated, may increase in 7 mg increments no more frequently than weekly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>). However, predicted steady state exposures are 60% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16413248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16413248'])">Ref</a></span>) to 100% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22863669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22863669'])">Ref</a></span>) greater compared to those with normal kidney function; a reduced maximum dose may be necessary in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: Initial: 7 mg once daily; after at least 1 week of therapy and if tolerated, may increase to a target dose of 14 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not likely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Dose as if the patient has a CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not likely to be significantly dialyzable (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Dose as if the patient has a CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT or PIRRT </b>
<b>(eg, sustained, low-efficiency diafiltration)</b>
<b>:</b> Not likely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Immediate release:</b> Dose as if the patient has a CrCl &lt;30 mL/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended release:</b> Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988478"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild-to-moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied); use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F192481"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F54820675"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Neuropsychiatric effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Neuropsychiatric effects, including <b>confusion</b>, <b>dizziness</b>, <b>drowsiness</b>, and <b>headache</b>, are the most commonly reported adverse reactions with memantine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15903287','lexi-content-ref-12409683']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15903287','lexi-content-ref-12409683'])">Ref</a></span>). <b>Ataxia</b>, <b>impaired consciousness</b>, <b>loss of consciousness</b>, <b>sleep disturbance</b>, <b>falling</b>, and <b>seizures</b> are among other CNS effects that have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34851866','lexi-content-ref-29881276','lexi-content-ref-33519428','lexi-content-ref-35272847','lexi-content-ref-37189266','lexi-content-ref-17030587','lexi-content-ref-16087923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34851866','lexi-content-ref-29881276','lexi-content-ref-33519428','lexi-content-ref-35272847','lexi-content-ref-37189266','lexi-content-ref-17030587','lexi-content-ref-16087923'])">Ref</a></span>). <b>Agitation, delusion, and hallucination </b>have also occurred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17030587','lexi-content-ref-16087923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17030587','lexi-content-ref-16087923'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Not clearly established; binds with low affinity to the phencyclidine (PCP) site at the N-methyl-D-aspartate (NMDA) receptor. PCP has a high affinity to the NMDA receptor and may cause psychotomimetic effects, such as agitation, delusions, and hallucinations. Patients with a concomitant dopamine/glutamate imbalance may be more susceptible to these effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17030587','lexi-content-ref-16087923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17030587','lexi-content-ref-16087923'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose titration may be a risk factor for transient confusion, especially in patients with severe dementia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19517247']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19517247'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">• Lewy body dementia, preexisting hallucinations, or concurrent use of a selective serotonin reuptake inhibitor may be risk factors for developing new-onset or worsening agitation, delusions, and hallucinations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17030587','lexi-content-ref-16087923']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17030587','lexi-content-ref-16087923'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F192451"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions similar in immediate and extended release formulations except as noted.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (4%), hypotension (ER: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Weight gain (ER: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (ER: 2%), constipation (3% to 5%), diarrhea (ER: 5%), vomiting (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (ER: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior (ER: 2%)<span class="lexi-table-link-container"> (<a aria-label="Aggressive Behavior table link" class="lexi-table-link" data-table-id="lexi-content-aggressive-behavior" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-aggressive-behavior')">table 1</a>)</span><span class="table-link" style="display:none;">Aggressive Behavior</span>, anxiety (ER: 4%)<span class="lexi-table-link-container"> (<a aria-label="Anxiety table link" class="lexi-table-link" data-table-id="lexi-content-anxiety" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-anxiety')">table 2</a>)</span><span class="table-link" style="display:none;">Anxiety</span>, confusion (IR: 6%)<span class="lexi-table-link-container"> (<a aria-label="Confusion table link" class="lexi-table-link" data-table-id="lexi-content-confusion" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-confusion')">table 3</a>)</span><span class="table-link" style="display:none;">Confusion</span>, depression (ER: 3%)<span class="lexi-table-link-container"> (<a aria-label="Depression table link" class="lexi-table-link" data-table-id="lexi-content-depression" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-depression')">table 4</a>)</span><span class="table-link" style="display:none;">Depression</span>, dizziness (5% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Dizziness table link" class="lexi-table-link" data-table-id="lexi-content-dizziness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-dizziness')">table 5</a>)</span><span class="table-link" style="display:none;">Dizziness</span>, drowsiness (3%)<span class="lexi-table-link-container"> (<a aria-label="Drowsiness table link" class="lexi-table-link" data-table-id="lexi-content-drowsiness" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-drowsiness')">table 6</a>)</span><span class="table-link" style="display:none;">Drowsiness</span>, fatigue (IR: 2%)<span class="lexi-table-link-container"> (<a aria-label="Fatigue table link" class="lexi-table-link" data-table-id="lexi-content-fatigue" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-fatigue')">table 7</a>)</span><span class="table-link" style="display:none;">Fatigue</span>, hallucination (IR: 3%)<span class="lexi-table-link-container"> (<a aria-label="Hallucination table link" class="lexi-table-link" data-table-id="lexi-content-hallucination" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hallucination')">table 8</a>)</span><span class="table-link" style="display:none;">Hallucination</span>, headache (6%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 9</a>)</span><span class="table-link" style="display:none;">Headache</span>, pain (IR: 3%)<span class="lexi-table-link-container"> (<a aria-label="Pain table link" class="lexi-table-link" data-table-id="lexi-content-pain" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-pain')">table 10</a>)</span><span class="table-link" style="display:none;">Pain</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Aggressive Behavior" frame="border" id="lexi-content-aggressive-behavior" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Aggressive Behavior</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Anxiety" frame="border" id="lexi-content-anxiety" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Anxiety</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Confusion" frame="border" id="lexi-content-confusion" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Confusion</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Depression" frame="border" id="lexi-content-depression" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Depression</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Dizziness" frame="border" id="lexi-content-dizziness" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Dizziness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Drowsiness" frame="border" id="lexi-content-drowsiness" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Drowsiness</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Fatigue" frame="border" id="lexi-content-fatigue" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Fatigue</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hallucination" frame="border" id="lexi-content-hallucination" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Hallucination</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Headache</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">ER tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Moderate to severe dementia of the Alzheimer's type</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">341</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">335</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Pain" frame="border" id="lexi-content-pain" rules="all">
<caption style="text-align:center;">
<b>Memantine: Adverse Reaction: Pain</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dosage Form</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Memantine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adults</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">IR tablets</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Dementia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">940</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">922</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (IR: 4%), dyspnea (IR: 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (Gallini 2008), heart failure (Gallini 2008), prolonged QT interval on ECG (Kajitani 2016), syncope (Curcio 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Fixed drug eruption (Saito 2017), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (Kose 2023), pancreatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis (Ferrara 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (Monastero 2007), ataxia (Ferreira 2020), delirium (Kose 2023), delusion (Ridha 2005), falling (Kose 2023), impaired consciousness (Kose 2023), loss of consciousness (Savić 2013), mania (Duan 2018), seizure (Ferreira 2020), sleep disturbance (Isaac 2022), suicidal ideation</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Kose 2023)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Epithelial keratopathy (Feng 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (Horikawa 2013)</p></div>
<div class="block coi drugH1Div" id="F192463"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to memantine or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F192449"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Rare skin hypersensitivity reactions (eg, Stevens-Johnson syndrome) have been reported; advise patients to report skin reactions immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease; although adverse cardiac events were infrequent in clinical trials, an increased incidence of cardiac failure, bradycardia, and hypertension/hypotension was observed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with severe hepatic impairment. The Canadian labeling recommends avoiding use in severe impairment due to a lack of data in this population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic disease: Worsening of corneal condition has been observed in a clinical trial. Reversible corneal endothelial dysfunction may occur; case report where noted around keratoplasty (Feng 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dose adjustments may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a history of seizure disorder; may increase risk of seizures.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Urine pH: Clearance is significantly reduced by alkaline urine; use caution with alkalinizing medications, dietary changes, or patient conditions that may increase urine pH.</p></div>
<div class="block foc drugH1Div" id="F192458"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namenda XR: 7 mg [DSC], 14 mg, 21 mg, 28 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namenda XR Titration Pack: 7 mg (7s) and 14 mg (7s) and 21 mg (7s) and 28 mg (7s) [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 7 mg, 14 mg, 21 mg, 28 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2 mg/mL (240 mL, 360 mL); 10 mg/5 mL (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namenda: 5 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namenda: 10 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Namenda Titration Pak: 5 mg (28s) and 10 mg (21s) [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 5 mg (28s) and 10 mg (21s)</p></div>
<div class="block geq drugH1Div" id="F192447"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F192465"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Memantine HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7 mg (per each): $15.26 - $15.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14 mg (per each): $15.26 - $15.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">21 mg (per each): $15.26 - $15.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 mg (per each): $15.26 - $15.28</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Namenda XR Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">14 mg (per each): $18.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">21 mg (per each): $18.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 mg (per each): $18.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Memantine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg/mL (per mL): $2.05 - $2.67</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Memantine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $6.04 - $8.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $6.04 - $8.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 x 5 MG &amp;21 x 10 MG (per each): $6.10</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Namenda Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $8.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $8.90</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Namenda Titration Pak Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">28 x 5 MG &amp;21 x 10 MG (per each): $8.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867459"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ebixa: 10 mg [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg</p></div>
<div class="block adm drugH1Div" id="F10450025"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer without regard to meals. Extended release capsules may be swallowed whole or entire contents of capsule may be sprinkled on applesauce and swallowed immediately; do not chew, crush, or divide. Withdraw and administer oral solution with provided dosing device; dose should be slowly squirted into the corner of the patient’s mouth. Do not mix oral solution with any other liquid. The Canadian labeling recommends tablets to be swallowed whole with water.</p></div>
<div class="block use drugH1Div" id="F192460"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease, moderate to severe:</b> Treatment of moderate to severe dementia of the Alzheimer type.</p></div>
<div class="block off-label drugH1Div" id="F25730710"><span class="drugH1">Use: Off-Label: Adult</span><p>Dementia (ie, Parkinson disease dementia, dementia with Lewy bodies, comorbid vascular dementia); Neurocognitive toxicity of whole brain irradiation, prevention</p></div>
<div class="block mst drugH1Div" id="F7828224"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Memantine may be confused with mesalamine, methadone</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299660"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OCT2</p></div>
<div class="block dri drugH1Div" id="F192453"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alkalinizing Agents: May increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: Memantine may diminish the therapeutic effect of Benperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbonic Anhydrase Inhibitors: May increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NMDA Receptor Antagonists: May enhance the adverse/toxic effect of Memantine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the adverse/toxic effect of Memantine. Specifically, the risk of myoclonus and/or delirium may be increased. Trimethoprim may increase the serum concentration of Memantine.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F192466"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in animal reproduction studies. </p></div>
<div class="block brc drugH1Div" id="F20616135"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if memantine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F11413651"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cognitive function; functional outcomes (eg, Activities of Daily Living [ADLs], Instrumental Activities of Daily Living [IADLs]); periodic ophthalmic exam (Canadian labeling)</p></div>
<div class="block pha drugH1Div" id="F192448"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Glutamate, the primary excitatory amino acid in the CNS, may contribute to the pathogenesis of Alzheimer's disease (AD) by overstimulating various glutamate receptors leading to excitotoxicity and neuronal cell death. Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) type of glutamate receptors, located ubiquitously throughout the brain. Under normal physiologic conditions, the (unstimulated) NMDA receptor ion channel is blocked by magnesium ions, which are displaced after agonist-induced depolarization. Pathologic or excessive receptor activation, as postulated to occur during AD, prevents magnesium from reentering and blocking the channel pore resulting in a chronically open state and excessive calcium influx. Memantine binds to the intra-pore magnesium site, but with longer dwell time, and thus functions as an effective receptor blocker only under conditions of excessive stimulation; memantine does not affect normal neurotransmission. </p></div>
<div class="block phk drugH1Div" id="F192462"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Well absorbed</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: 9 to 11 L/kg </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 45% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Partially hepatic, primarily independent of the CYP enzyme system; forms 3 metabolites (minimal activity) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: Terminal: ~60 to 80 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release: 3 to 7 hours; Extended release: 9 to 12 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (74%; ~48% of the total dose as unchanged drug; undergoes active tubular secretion moderated by pH-dependent tubular reabsorption; excretion reduced by alkaline urine pH) </p></div>
<div class="block phksp drugH1Div" id="F51159447"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Mean AUC<sub>0-∞</sub> increased by 4%, 60%, and 115% in patients with mild, moderate, and severe renal impairment, respectively. The terminal elimination half-life increased by 18%, 41%, and 95% in patients with mild, moderate, and severe renal impairment, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Terminal elimination half-life increased by ~16% in patients with moderate hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Women had ~45% greater exposure than men; however, there was no difference in exposure when body weight was taken into account.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F192468"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Ebimenta | Ebixa | Zementa</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Akatinol | Carrier | Carrier xr | Conexine | Ebixa | Exem | Fentina | Lucidex | Lucidex xr | Memantina richet | Memantina teva | Merital | Neuroplus | Neuroplus xr 7/14/21/28 | Precel | Prilben | Recorine | Tonibral | Tonibral xr</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Axura | Ebixa | Memantin 1a pharma | Memantin accord | Memantin easypharm | Memantin g.l. | Memantin genericon | Memantin HCS | Memantin ratiopharm | Memantin sandoz | Memantin stada | Memantine merz</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo memantine | Ebixa | Memantine generichealth | Memantine rbx | Memanxa</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Abixa | Dementa | Memogen | Remtin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memantine | Memantine abdi | Memantine apotex | Memantine eg | Memantine lek | Memantine sandoz | Memantine Teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Axura | Memantine | Memigmin | Mexia | Nemdatine | Polmatine | Ymana</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Alois | Alz | Clomenac | Cloridarto de memantina | Cloridrato de memantina | Desiree | Ebix | Heimer | Kamppi | Maizher | Mealz | Memorall | Vie | Zider</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Axura | Ebixa | Memantin mepha | Memantin sandoz | Memantin zentiva</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dantex | Ebixa | Mebral | Memanvitae | Memax | Memikare | Merital | Mimetix | Vivimex</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memantine hydrochloride tablets</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Admenta 10 | Airzat | Akatinol | Alzantina | Biogaran | Cordure | Dinive | Ebixa | Esmirtal | Eutebrol | Lucidex | Memantina | Memanvitae | Memdrive | Memorex | Memoxil | Modualz | Normokin | Timantil | Valcox | Vigentia | Zeimer</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Cognomem | Ebixa | Mantomed | Marixino | Memantin apotex | Memantin mylan | Memantin sandoz | Memantin stada | Memantin zentiva | Memantine accord | Memantine aurovitas | Memantine Glenmark | Memantine ratiopharm | Memantine vipharm | Memigmin | Memixa | Memolan | Mirvedol | Morysa | Nemdatine | Polmatine | Tormoro</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Axura | Ebixa | Memando | Memangeneri initial | Memantigamma | Memantin 1a pharma | Memantin Aaa Pharma | Memantin abdi | Memantin abz | Memantin accord | Memantin aristo | Memantin Aurobindo | Memantin basics | Memantin hcl Zentiva | Memantin Heumann | Memantin Hexal | Memantin mylan | Memantin puren | Memantin ratiopharm | Memantin winthrop | Memantine merz | Memantinhydrochlorid al | Memantinhydrochlorid axcount | Memantinhydrochlorid hormosan | Memantinhydrochlorid Macleods | Memantinhydrochlorid neuraxpharm | Memantinhydrochlorid puren | Memantinhydrochlorid stada | Memdub | Memolan | Memutz</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Akatinol | Akatinol Memantina | Carrier | Cordure | Demantin | Esmirtal | Eurodementina | Eutebrol | Memantin | Memantina mk | Memanvitae | Mimetix | Neuroplus | Pilsol | Proconex | Rebrain | Tonibral</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Acepter | Admenta | Carrier xr | Cognum | Esmirtal | Eutebrol | Lindex | Lucidex | Memantina | Memantina hcl | Mimetix | Neuroplus</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Axura | Cognomem | Mantomed | Marixino | Memantine accord | Memantine grindeks | Memantine ratiopharm | Nemdatine | Xapimant</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alzixa | Alzmenda | Condomania | Delmenda | Dementexa | Ebixa | Lurvntel | Mantine | Memantcare | Memexa | Ravemantine | Zalhinapex</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Axura | Ebixa | Lonrela | Mantinex | Marixino | Memabix | Memantina accord | Memantina alter | Memantina apotex | Memantina Aristo | Memantina aurobindo | Memantina cinfa | Memantina kern pharma | Memantina mabo | Memantina mylan | Memantina normon | Memantina pensa | Memantina pharma combix | Memantina pharmagenus | Memantina qualigen | Memantina ranbaxy | Memantina ratiopharm | Memantina sandoz | Memantina stada | Memantina tarbis | Memantina tecnigen | Memantina teva | Memantina vir | Memantina zentiva | Nabila | Nemdatine | Protalon | Uxamax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Adaxor | Ebixa | Marbodin | Memantin orion | Memantine accord | Memantine lek | Memantine merz | Memantine ratiopharm | Memantine sandoz | Mentixa | Nemdatine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memantine actavis | Memantine almus | Memantine biogaran | Memantine cristers | Memantine eg | Memantine evolugen | Memantine hcs | Memantine lek | Memantine mylan | Memantine Ohre pharma | Memantine ranbaxy | Memantine sandoz | Memantine Teva | Memantine zentiva | Memantine zydus france</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Maruxa | Memantine | Memantine accord | Memantine Glenmark | Memantine hydrochloride Zentiva | Memantine sandoz | Nemdatine</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cognomem | Ebimem | Ebixa | Mantomed | Marixino | Memantine merz | Memantine mylan | Memantine/ariti | Memantine/sandoz | Memantine/teva | Memasolv | Memini | Mentifar | Mobius | Nemdatine | Zolmemin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Albix | Apo memantine | Ebixa | Marixino | Memantine actavis | Memantine sandoz | Pms memantine</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memando | Memantin PharmaS | Memantin Pliva | Ymana</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Ebixa | Memantin stada | Memantine orion | Memantine ranbaxy | Memantine vipharm | Mirvedol | Morysa | Nemdatine</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Abixa | Nemdatine | Pertam</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Marixino | Maruxa | Memantine | Memantine accord | Memantine clonmel | Memantine Hydrochloride Niche | Memantine hydrochloride pinewood | Memantine lek | Memantine ratiopharm | Nemdatine</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memox</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Admenta | Almantin | Alzitin | Axura | Demenzil | Ebixa | Larentine | Mentadem | Mentra | Nemdaa</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Nemdatine | Zalatine</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Ezemantis | Marixino | Memantina accord | Memantina aurobindo | Memantina doc generici | Memantina lek | Memantina mylan | Memantina sandoz | Memantina tecnigen | Solemantis</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Demax | Ebixa | Gladius | Mirale | Tabixa</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Memary</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Foliant | Stir Up</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Admed | Akatinol | Albix | Almantin | Almix | Altsumetin | Amentin | Bl memantine | Dementine | Dimantine | Diments | Dimenza | Dongkoo memantine hcl | Dongwha memantine | Easymantine | Ebixa | Ebixia | Eisatine | Emantin | Fello | Glivixa | Mabigs | Mamantin | Mamobixa | Mantini | Mavis | Mebix | Memanten | Memanti | Memantia | Memantigen | Memantil | Memantine | Memanto | Memanzen | Memanzin | Memixa | Memoratine | Memotin | Menobixa | Mevitan | Momentine | Neuro K | Neuronal | Newmantine | Pms memantine | Prometine | Romantin | Samantine | Samsung memantine | Unex | Wi memantine | Zenbixa | Zymer</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Tabixa</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alzema | Ebimenta | Ebixa | Memantine Arrow Lab | Memantine biogaran | Memora | Pms memantine</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Axura | Cognomem | Mantomed | Marixino | Maryzola | Memantine accord | Memantine grindeks | Memantine orion | Memantine ratiopharm | Nemdatine | Polmatine | Xapimant</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Akatinol | Axura | Ebixa | Memantine eg | Memantine merz | Memantine ratiopharm | Memantine sandoz</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Axura | Ebixa | Marixino | Memantine accord | Memantine grindeks | Memantine orion | Memantine ratiopharm | Nemdatine | Polmatine</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Almantin | Memantine gt | Phipixa</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acepter | Akatinol | Alzeti | Cediav In | Cediavin | Ebixa | Eutebrol | Ezagun | Keptic | Linybindo | Matinev | Mechanun | Memantina | Menural | Mimetice | Muvixden | Nemet | Perduquan | Sytine | Tejaswi | Ziyol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Macmenta | Marixino | Mementor | Memxa</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memantine | Memantine abdi | Memantine accord | Memantine cf | Memantine mylan | Memantine sandoz | Memantine Teva | Nemdatine</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memantin accord | Memantine ratiopharm | Nemdatine</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ebixa</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Admenta | Akatinol | Clauss | Depsert | Esmirtal | Eutebrol | Lemix | Mardewel | Meanti | Memantina | Memanvitae | Merital | Mimetix | Talentum</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Abixa | Amint | Cognitine | Denigma | Memadem | Memry | Mentra | Xapimant | Zimerz</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Afdol | Akatinol | Alzagon | Alzamantine | Alzentine | Contine | Demantin | Ebixa | Foliant | Mamgit | Mantex | Mantin | Mantine | Memlip | Memril | Namentec | Rement | Rementia | Stir Up | Synaptin | Xantol | Zexa | Zilment</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Auromemo | Axura | Biomentin | Cognomem | Ebixa | Marbodin | Marixino | Memabix | Memantin NeuroPharma | Memantine accord | Memantine Glenmark | Memantine mylan | Memantine orion | Memantine Teva | Memantine vipharm | Memigmin | Memolek | Merandex | Mirvedol | Morysa | Nemdatine | Nemedan | Polmatine | Tormoro</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Memantine HCL | Namenda | Namenda xr</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Axura | Ebixa | Memantina alter | Memantina Aluzime | Memantina Aristo | Memantina aurobindo | Memantina aurovitas | Memantina Bluepharma | Memantina ciclum | Memantina Farmoz | Memantina Generis | Memantina Jaba | Memantina krka | Memantina Labesfal | Memantina lek | Memantina mylan | Memantina pentafarma | Memantina pharmacons | Memantina pharmakern | Memantina ratiopharm | Memantina tecnigen | Memantina Tecnilor | Memantina teva | Memantina toLife | Memantina zentiva | Memantine Teva | Nemdatine</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Akatinol | Carrier | Eutebrol | Fulplex | Lucidex | Megavital | Memantil | Memantina promepar | Memax | Memoral | Mimetix</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Demax | Ebixa | Gladius | Memoria | Tabixa</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cognomen | Ebixa | Mantomed | Marixino | Maruxa | Memantina aurobindo | Memantina torrent | Memantine accord | Xapimant</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Akatinol memantine | Alzeim | Auranex | Maruxa | Marvedol | Memantal | Memantin | Memantin Kanon | Memantin tl | Memantine | Memantine akrikhin | Memantine avexima | Memantine canon | Memantine richter | Memantine sandoz | Memantine tl | Memantinol | Memicar | Memorel | Noojerone | Noojerone teva | Tingreks | Zemotine</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo memantine | Ebixa | Espada | Marlon | Memaxia | Mementa | Tabixa | Zementa</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Marbodin | Memantin Ebb | Memantin orion | Memantin stada | Memantine accord | Memantine lek | Memantine merz | Memantine mylan | Memantine ratiopharm | Memantine sandoz | Mentixa | Nemdatine</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Marixino | Nemdatine</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Marbodin | Maruxa | Memantin | Memantin accord | Memantine merz | Memantine mylan | Memaxa | Xapimant | Ymana</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Mantomed | Marixino | Memamed | Memantin stada | Memantine accord | Memantine Glenmark | Memantine mylan | Memantine ratiopharm | Memantine vipharm | Memigmin | Memolan | Morysa | Nemdatine | Polmatine | Xapimant</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Memxa | Neumantine | Remem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Appelom | Ebixa | Memixa</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alceba | Almenta | Alzant | Alzer | Alzia | Alzmex | Angetin | Ceramin | Cogito | Demax | Ebitex | Ebixa | Korint | Maxiram | Melanda | Memanzaks | Memorix | Mentax | Mexia | Mexia xr | Xeimer</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Ebixa | Exmem | Manotin | Memary | Witgen</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Abixa | Admenta | Cognimet | Denigma | Mema | Memamed | Memantine Teva | Mematon ic | Membral | Memox | Mexia | Mirvedol | Neurontin | Tingrex</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Akatinol | Eutebrol | Glutamod | Neuroplus | Tonibral</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cognimet | Esmirtal | Eutebrol | Meligen | Memantina | Memantina Bluepharma | Memantine | Mezhitin | Mimetix | Timantil</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cognimet 10 | Ebitine | Memantine unichem | Meminist | Memor | Noalzh</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Mementor</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-19520613">
<a name="19520613"></a>Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurol.</i> 2009;8(7):613-618. doi:10.1016/S1474-4422(09)70146-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/19520613/pubmed" id="19520613" target="_blank">19520613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34851866">
<a name="34851866"></a>Bago Rožanković P, Rožanković M, Badžak J, Stojić M, Šušak Sporiš I. Impact of donepezil and memantine on behavioral and psychological symptoms of Alzheimer disease: six-month open-label study. <i>Cogn Behav Neurol</i>. 2021;34(4):288-294. doi:10.1097/WNN.0000000000000285<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/34851866/pubmed" id="34851866" target="_blank">34851866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25523285">
<a name="25523285"></a>Ballard C, Thomas A, Gerry S, et al. MAIN-AD investigators. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD). <i>J Am Med Dir Assoc. </i>2015;16(4):316-322.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/25523285/pubmed" id="25523285" target="_blank">25523285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058845">
<a name="32058845"></a>Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. <i>J Clin Oncol.</i> 2020;38(10):1019-1029. doi:10.1200/JCO.19.02767<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/32058845/pubmed" id="32058845" target="_blank">32058845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23956241">
<a name="23956241"></a>Brown PD, Pugh S, Laack NN, et al; Radiation Therapy Oncology Group (RTOG). Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. <i>Neuro Oncol</i>. 2013;15(10):1429-1437. doi:10.1093/neuonc/not114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23956241/pubmed" id="23956241" target="_blank">23956241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30872082">
<a name="30872082"></a>Curcio F, Testa G, Ceccofiglio A, et al. Memantine Induces reflex syncope in elderly patients with dementia: results from the syncope and dementia study (SYD-Study). <i>J Am Med Dir Assoc</i>. 2020;21(1):130-132. doi:10.1016/j.jamda.2019.01.124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/30872082/pubmed" id="30872082" target="_blank">30872082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23411693">
<a name="23411693"></a>Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease. <i>J Alzheimers Dis.</i> 2013;35(2):349-361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23411693/pubmed" id="23411693" target="_blank">23411693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29881276">
<a name="29881276"></a>Duan J, Lao C, Chen J, et al. Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report. <i>Neuropsychiatr Dis Treat</i>. 2018;14:1395-1398. doi:10.2147/NDT.S160832<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/29881276/pubmed" id="29881276" target="_blank">29881276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lundbeck.1">
<a name="Lundbeck.1"></a>Ebixa (memantine) [product monograph]. Montreal, Quebec, Canada: Lundbeck Canada Inc; May 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20729148">
<a name="20729148"></a>Emre M, Tsolaki M, Bonuccelli U, et al; 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. <i>Lancet Neurol.</i> 2010;9(10):969-977. doi:10.1016/S1474-4422(10)70194-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/20729148/pubmed" id="20729148" target="_blank">20729148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26248040">
<a name="26248040"></a>Feng MT, Price FW Jr, McKee Y, Price MO. Memantine-associated corneal endothelial dysfunction. <i>JAMA Ophthalmol</i>. 2015;133(10):1218-1220. doi:10.1001/jamaophthalmol.2015.2476<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/26248040/pubmed" id="26248040" target="_blank">26248040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413635">
<a name="18413635"></a>Ferrara N, Corbi G, Capuano A, Filippelli A, Rossi F. Memantine-induced hepatitis with cholestasis in a very elderly patient. <i>Ann Intern Med</i>. 2008;148(8):631-632. doi:10.7326/0003-4819-148-8-200804150-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/18413635/pubmed" id="18413635" target="_blank">18413635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33519428">
<a name="33519428"></a>Ferreira TR, Lopes LC, Bergamaschi CC. Frequency and severity of adverse drug reactions to medications prescribed for Alzheimer's disease in a Brazilian city: cross-sectional study. <i>Front Pharmacol.</i> 2020;11:538095. doi:10.3389/fphar.2020.538095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/33519428/pubmed" id="33519428" target="_blank">33519428</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22567095">
<a name="22567095"></a>Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. <i>PLoS One.</i> 2012;7(5):e35185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/22567095/pubmed" id="22567095" target="_blank">22567095</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18500725">
<a name="18500725"></a>Gallini A, Sommet A, Montastruc JL; French PharmacoVigilance Network. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(9):877-881. doi:10.1002/pds.1620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/18500725/pubmed" id="18500725" target="_blank">18500725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23733403">
<a name="23733403"></a>Grossberg GT, Manes F, Allegri RF, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. <i>CNS Drugs</i>. 2013;27(6):469-478. doi:10.1007/s40263-013-0077-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23733403/pubmed" id="23733403" target="_blank">23733403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23438167">
<a name="23438167"></a>Horikawa N, Yamada H, Uchimura N. Memantine-associated renal impairment in a patient with Alzheimer's disease. <i>Psychiatry Clin Neurosci</i>. 2013;67(2):126. doi:10.1111/pcn.12020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23438167/pubmed" id="23438167" target="_blank">23438167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22397651">
<a name="22397651"></a>Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. <i>N Engl J Med</i>. 2012;366(10):893-903. doi:10.1056/NEJMoa1106668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/22397651/pubmed" id="22397651" target="_blank">22397651</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35272847">
<a name="35272847"></a>Isaac E, Ney D, Serruya M, Keith S, Lippa C, Sperling MR. Tolerability of memantine monotherapy versus adding memantine as combination therapy. <i>J Natl Med Assoc</i>. 2022;114(3):308-313. doi:10.1016/j.jnma.2022.02.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/35272847/pubmed" id="35272847" target="_blank">35272847</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17243195">
<a name="17243195"></a>Jones RW, Bayer A, Inglis F, Barker A, Phul R. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.<i> Int J Geriatr Psychiatry</i>. 2007;22(3):258-262. doi:10.1002/gps.1752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/17243195/pubmed" id="17243195" target="_blank">17243195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26782892">
<a name="26782892"></a>Kajitani K, Yanagimoto K, Monji A, Maruyama T. Memantine exacerbates corrected QT interval prolongation in Alzheimer's disease: a case report from an unintentional rechallenge. <i>J Am Geriatr Soc</i>. 2016;64(1):232-233. doi:10.1111/jgs.13897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/26782892/pubmed" id="26782892" target="_blank">26782892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17689146">
<a name="17689146"></a>Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. <i>Lancet Neurol</i>. 2007;6(9):782-792. doi:10.1016/S1474-4422(07)70195-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/17689146/pubmed" id="17689146" target="_blank">17689146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37189266">
<a name="37189266"></a>Kose E, Yamamoto T, Tate N, Ando A, Enomoto H, Yasuno N. Adverse drug event profile associated with anti-dementia drugs: analysis of a spontaneous reporting database. <i>Pharmazie</i>. 2023;78(5):42-46. doi:10.1691/ph.2023.2584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/37189266/pubmed" id="37189266" target="_blank">37189266</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19517247">
<a name="19517247"></a>Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA. Efficacy and safety of memantine in Lewy body dementia. <i>Neurosci Behav Physiol</i>. 2009;39(6):597-604. doi:10.1007/s11055-009-9167-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/19517247/pubmed" id="19517247" target="_blank">19517247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891742">
<a name="30891742"></a>McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. <i>Cochrane Database Syst Rev</i>. 2019;3:CD003154. doi:10.1002/14651858.CD003154.pub6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/30891742/pubmed" id="30891742" target="_blank">30891742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Seton.1">
<a name="Seton.1"></a>Memantine Hydrochloride [prescribing information]. Wall, NJ: Seton Pharmaceuticals; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17030587">
<a name="17030587"></a>Monastero R, Camarda C, Pipia C, Camarda R. Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. <i>J Neurol Neurosurg Psychiatry</i>. 2007;78(5):546. doi:10.1136/jnnp.2006.096420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/17030587/pubmed" id="17030587" target="_blank">17030587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22863669">
<a name="22863669"></a>Moritoyo T, Hasunuma T, Harada K, et al. Effect of renal impairment on the pharmacokinetics of memantine.<i> J Pharmacol Sci</i>. 2012;119(4):324-329. doi:10.1254/jphs.12043fp<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/22863669/pubmed" id="22863669" target="_blank">22863669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.1">
<a name="Allergan.1"></a>Namenda (memantine) [prescribing information]. Madison, NJ: Allergan USA Inc; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.2">
<a name="Allergan.2"></a>Namenda XR (memantine) [prescribing information]. Madison, NJ: Allergan USA Inc; November 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Allergan.3">
<a name="Allergan.3"></a>Namenda XR Titration Pack (memantine) [prescribing information]. Irvine, CA: Allergan USA, Inc; October 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2018">
<a name="NICE.2018"></a>National Institute for Health and Care Excellence (NICE). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline 97. https://www.nice.org.uk/guidance/ng97/evidence/full-guideline-pdf-4852695709. Published June 2018. Accessed March 31, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2017">
<a name="NICE.2017"></a>National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. NICE guideline 71. https://www.nice.org.uk/guidance/ng71/resources/parkinsons-disease-in-adults-pdf-1837629189061. Published July 19, 2017. Accessed June 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28103749">
<a name="28103749"></a>O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology.<i> J Psychopharmacol.</i> 2017;31(2):147-168. doi:10.1177/0269881116680924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/28103749/pubmed" id="28103749" target="_blank">28103749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15745897">
<a name="15745897"></a>Peltz G, Pacific DM, Noviasky JA, Shatla A, Mehalic T. Seizures associated with memantine use. <i>Am J Health Syst Pharm</i>. 2005;62(4):420-421. doi:10.1093/ajhp/62.4.0420<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/15745897/pubmed" id="15745897" target="_blank">15745897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16413248">
<a name="16413248"></a>Periclou A, Ventura D, Rao N, Abramowitz W. Pharmacokinetic study of memantine in healthy and renally impaired subjects. <i>Clin Pharmacol Ther.</i> 2006;79(1):134-143. doi:10.1016/j.clpt.2005.10.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/16413248/pubmed" id="16413248" target="_blank">16413248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18288936">
<a name="18288936"></a>Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.<i> Curr Alzheimer Res.</i> 2008;5(1):83-89. doi:10.2174/156720508783884576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/18288936/pubmed" id="18288936" target="_blank">18288936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30771226">
<a name="30771226"></a>Reeve E, Farrell B, Thompson W, et al. Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary. <i>Med J Aust.</i> 2019;210(4):174-179. doi:10.5694/mja2.50015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/30771226/pubmed" id="30771226" target="_blank">30771226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16087923">
<a name="16087923"></a>Ridha BH, Josephs KA, Rossor MN. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. <i>Neurology</i>. 2005;65(3):481-482. doi:10.1212/01.wnl.0000172351.95783.8e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/16087923/pubmed" id="16087923" target="_blank">16087923</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15903287">
<a name="15903287"></a>Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. <i>Am J Geriatr Pharmacother</i>. 2004;2(4):303-312. doi:10.1016/j.amjopharm.2004.12.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/15903287/pubmed" id="15903287" target="_blank">15903287</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28668245">
<a name="28668245"></a>Saito R, Sawada Y, Yamaguchi T, et al. Drug eruption caused by memantine. <i>Ann Allergy Asthma Immunol</i>. 2017;119(1):89-90. doi:10.1016/j.anai.2017.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/28668245/pubmed" id="28668245" target="_blank">28668245</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23415840">
<a name="23415840"></a>Savić A, Mimica N. Two cases of loss of consciousness after long-term memantine treatment. <i>J Am Med Dir Assoc</i>. 2013;14(5):375-376. doi:10.1016/j.jamda.2013.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/23415840/pubmed" id="23415840" target="_blank">23415840</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12409683">
<a name="12409683"></a>Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). <i>Int Clin Psychopharmacol</i>. 2002;17(6):297-305. doi:10.1097/00004850-200211000-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/memantine-drug-information/abstract-text/12409683/pubmed" id="12409683" target="_blank">12409683</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10131 Version 494.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
